Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Katja Björklöf"'
Publikováno v:
Biotechnology & Biotechnological Equipment, Vol 38, Iss 1 (2024)
Bulgarian real-world data on denosumab use for the prevention of skeletal-related events (SREs) associated with bone metastases (BM) from prostate cancer (PC) are lacking. This observational study enrolled 100 adult PC patients with ≥1 BM receiving
Externí odkaz:
https://doaj.org/article/61c41b94e4a24cd19e4478785e911fdf
Autor:
Jane Hippenmeyer, Nikolai Tzvetkov, Katja Björklöf, Zuzana Sninska, Vladlen Ivanushkin, Georgi Mihaylov, Barbara Skopec
Publikováno v:
Hematology. 26:497-502
OBJECTIVES The objective of this analysis was to assess the effectiveness and safety of romiplostim in the real-world by duration of primary immune thrombocytopenia (ITP): 12 ('chronic') months. METHODS This was a post-hoc analysis of the PLATON sing
Autor:
Peter Černelč, Vladlen Ivanushkin, Nikolai Tzvetkov, Barbara Skopec, Katja Björklöf, Georgi Mihaylov, Daniela Niepel, Zuzana Sninska, O. Černá
Publikováno v:
memo - Magazine of European Medical Oncology. 13:227-234
SummaryChronic primary immune thrombocytopenia (ITP) is an autoimmune disease involving the formation of antibodies to thrombocytes, leading to increased platelet destruction and chronic thrombocytopenia. Additionally, impaired platelet production is
Autor:
Katja Björklöf, Daniela Niepel, Richard Greil, Antoaneta Tomova, Miriam Porubska, Martin Safanda, Andreas L. Petzer, Christine Jaeger, Zoltán Bajory, Dmitry Kalinin, Ferdinand Haslbauer
Publikováno v:
Supportive Care in Cancer
Purpose In the integrated analysis of phase III head-to-head trials in patients with advanced solid tumors, denosumab demonstrated superiority over zoledronic acid in preventing skeletal-related events (SREs). Regular and continued drug use (persiste
Autor:
Holger Hebart, George Kafatos, Anja Kuhn, Jiri Tomasek, Michael G. Kiehl, Katja Björklöf, Reija Koukakis, Gaston Demonty, Tomas Buchler, Tibor Csoszi
Publikováno v:
Advances in Therapy
Introduction This study aimed to better understand panitumumab use in real-life clinical practice in first- and second-line treatment of metastatic colorectal cancer in five European countries. Methods This is a combined analysis of two observational
Autor:
Imrich Markuljak, Ivan Spicka, Leah Fink, Daniel Coriu, Georgi Mihaylov, Katja Björklöf, Slobodanka Ostojic-Kolonic, Krisztian S Toka, Dominik Dytfeld, Daniela Niepel
Publikováno v:
Polish Archives of Internal Medicine.
Introduction Multiple myeloma (MM) treatment has evolved substantially in recent years. Solid data on the impact of treatment strategies on patient outcomes beyond clinical trials are scarce, especially in budget‑restricted environments with limite
Autor:
M Hemetsberger, F Gatta, Katja Björklöf, D Dytfeld, Daniel Coriu, Daniela Niepel, KS Toka, Leah Fink
Publikováno v:
Value in Health. 20:A459-A460
Autor:
Katja Björklöf, Tibor Csoszi, Jiri Tomasek, Holger Hebart, George Kafatos, Tomas Buchler, Reija Koukakis, Anja Kuhn
Publikováno v:
Journal of Clinical Oncology. 36:852-852
852 Background: This study aimed to understand panitumumab (pmab) use in clinical practice for patients with wild-type RAS metastatic colorectal cancer (mCRC), in first-line (1L) with FOLFOX or second-line (2L) with FOLFIRI following fluoropyrimidine
Autor:
Peter J. Greasley, Laura Stanasila, Susanna Cotecchia, Olivier Rossier, Francesca Fanelli, Katja Björklöf
Publikováno v:
Journal of Receptors and Signal Transduction. 22:1-16
The aim of this review is to summarize some of the main findings from our laboratory as well as from others concerning the biochemical, molecular, and functional properties of the alpha1b-adrenergic receptor. Experimental and computational mutagenesi
Autor:
Susanna Cotecchia, Laura Stanasila, Dario Diviani, Katja Björklöf, Olivier Rossier, Francesca Fanelli
The aim of a large number of studies on G protein-coupled receptors was centered on understanding the structural basis of their main functional properties. Here, we will briefly review the results obtained on the alpha1-adrenergic receptor subtypes b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a5dc6d31f9c03df146fa47af9fa0e7b
https://hdl.handle.net/11380/584270
https://hdl.handle.net/11380/584270